The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients

Archives of Dermatological Research

Volumn 307, Issue 5, 2015, Pages 405-412

  González Lara, Leire ^a   Batalla, Ana ^a   Coto, Eliecer ^a,b   Gómez, Juan ^a   Eiris, Noemí ^a   Santos Juanes, Jorge ^a   Queiro, Rubén ^a   Coto Segura, Pablo ^a,b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Biological therapy; Gene polymorphism; Next generation sequencing; Pharmacogenetic; Psoriasis

Indexed keywords

ADALIMUMAB; AMINO ACID; ARGININE; BIOLOGICAL PRODUCT; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23 ANTIBODY; METHIONINE; METHOTREXATE; NUCLEOTIDE; TNFRSF1A PROTEIN; TNFRSF1B PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; USTEKINUMAB; TNFRSF1B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RISK FACTOR; SEMICONDUCTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; CHEMISTRY; DRUG RESISTANCE; GENETICS; MIDDLE AGED; PHARMACOGENETICS; PROCEDURES; SEQUENCE ANALYSIS;

ADULT; BIOLOGICAL THERAPY; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEQUENCE ANALYSIS, PROTEIN;

EID: 84931566035     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-014-1533-z     Document Type: Article

References (34)

1. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C et al (2007) Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 122:201–206
2. Cordoro KM, Feldman SR (2007) TNF-alpha inhibitors in dermatology. Skin Therapy Lett 12:4–6
3. Eiris N, González-Lara L, Santos-Juanes J, Queiro R, Coto E, Coto Segura P (2014) Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. J Dermatol Sci 75:167–172
4. Flanagan SE, Patch AM, Ellard S (2010) Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genet Test Mol Biomarkers 14:533–537
5. Gallo E, Cabaleiro T, Román M et al (2013) The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study. Br J Dermatol 169:819–829
6. Glossop JR, Dawes PT, Nixon NB et al (2005) Polymorphism in the tumor necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther 7:R1227–R1234
7. Gómez J, Reguero JR, Morís C, Alvarez V, Coto E (2014) Non optical semi-conductor next generation sequencing of the main cardiac QT-interval duration genes in pooled DNA samples. J Cardiovasc Transl Res 7:133–137
8. González-Lara L, Coto-Segura P, Penedo A, Eiris N, Díaz M et al (2013) SNP rs11652075 in the CARD14 gene as a risk factor for psoriasis (PSORS2) in a Spanish cohort. DNA Cell Biol 32:601–604
9. Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L et al (2012) Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNF alpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 22:577–589
10. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R et al (2008) Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in Rheumatoid Arthritis. Mol Med 14:575–581
11. Mason A, Mason J, Cork M, Hancock H, Dooley G (2013) Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. J Am Acad Dermatol 69:799–807
12. Medrano LM, Taxonera C, Márquez A, Barreiro-de Acosta M, Gómez-García M et al (2014) Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab. Hum Immunol 75:71–75
13. Miller DW, Feldman SR (2006) Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother 7:157–167
14. Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y et al (2001) Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 44:2819–2827
15. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T et al (2008) Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 128:1653–1661
16. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S et al (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78:827–851
17. Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW et al (2011) Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 63:645–653
18. Riveira-Munoz E, He SM, Escaramís G, Stuart PE, Hüffmeier U et al (2011) Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol 131:1105–1109
19. Rooryck C, Barnetche T, Richez C, Laleye A, Arveiler B et al (2008) Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 26:340–342
20. Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ et al (2003) Tumor necrosis factor receptor type II 196 M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 76:1742–1749
21. Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen O et al (2012) Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn’s disease. Aliment Pharmacol Ther 36:650–659
22. Strange A, Capon F, Spencer CC, Knight J, Weale ME et al (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42:985–990
23. Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G et al (2013) Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 169:458–463
24. Tang H, Jin X, Li Y, Jiang H, Tang X et al (2014) A large-scale screen for coding variants predisposing to psoriasis. Nat Genet 46:45–50
25. Tejasvi T, Stuart PE, Chandran V, Voorhees JJ, Gladman DD et al (2012) TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 132:593–600
26. Thomas VD, Yang FC, Kvedar JC (2005) Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 53:346–351
27. Till A, Rosenstiel P, Krippner-Heidenreich A et al (2005) The Met196>arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem 280:5994–6004
28. Tolusso B, Sacco S, Gremese E, La Torre G, Tomietto P et al (2004) Relationship between the tumor necrosis factor receptor II (TNF-RII) gene polymorphism and sTNF-RII plasma levels in healthy controls and in rheumatoid arthritis. Hum Immunol 65:1420–1426
29. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE et al (2012) Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 44:1341–1348
30. Vasilopoulos Y, Bagiatis V, Stamatopoulou D, Zisopoulos D, Alexiou I et al (2011) Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis. Clin Exp Rheumatol 29:701–704
31. Vasilopoulos Y, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V et al (2012) Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther 16:29–34
32. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH et al (2009) Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 160:438–441
33. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M et al (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204:3183–3194
34. Zheng HF, Zuo XB, Lu WS, Li Y, Cheng H, Zhu KJ et al (2011) Variants in MHC, LCE and IL12B have epistatic effects on psoriasis risk in Chinese population. J Dermatol Sci 61:124–128